Monoamine Oxidase Inhibitors in Patients With Chronic Pain

Davidson, Jonathan

doi:10.1001/archpsyc.1985.01790290117018

Cited by 16 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, this study also found that phenelzine was more effective than amitriptyline, and the investigators speculated that this difference might be due to the presence of atypical depressive symptoms (i.e.,, hyperphagia and weight gain) [72]. Such a difference in efficacy between tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors is consistent with a similar finding in the treatment of dysthymia [6, 1461.…”

Section: Treatment Implications Of Medical Comorbidity In Dysthymiasupporting

confidence: 75%

General Health, Health Care Utilization, and Medical Comorbidity in Dysthymia

Howland

1993

Int J Psychiatry Med

View full text Add to dashboard Cite

Although dysthymia is considered a minor depressive condition, these findings show that it is a significant public health problem, comparable to major depression. Recent efforts to improve the recognition and treatment of major depression in medical settings, therefore, should be extended to include the entire spectrum of depressive disorders. Future studies should investigate the type and pattern of medical comorbidity and health care utilization, different antidepressant and psychosocial therapies, and the clinical and biological correlates of treatment response in different chronic depressive subtypes in medical settings and compare them to major depressive and subsyndromal depressive conditions.

show abstract

Section: Treatment Implications Of Medical Comorbidity In Dysthymiasupporting

confidence: 75%

General Health, Health Care Utilization, and Medical Comorbidity in Dysthymia

Howland

1993

Int J Psychiatry Med

View full text Add to dashboard Cite

show abstract

“…Such versatility of hydrazine-containing drugs may indicate their potential to be repurposed and/or optimized for the treatment of other CNS diseases. Indeed, phenelzine is known to have antiaddictive effects, 50 , 51 and MAOIs have reported efficacy for fibromyalgia, 52 pain, 53 bipolar disorder, 54 Parkinson’s disease, 55 and multiple-system atrophy. 56 Taken together, these facts indicate that MAOIs and their targets have druggable potential for a broad spectrum of brain diseases.…”

Section: Discussionmentioning

confidence: 99%

Activity-Based Hydrazine Probes for Protein Profiling of Electrophilic Functionality in Therapeutic Targets

et al. 2021

View full text Add to dashboard Cite

Most known probes for activity-based protein profiling (ABPP) use electrophilic groups that tag a single type of nucleophilic amino acid to identify cases in which its hyper-reactivity underpins function. Much important biochemistry derives from electrophilic enzyme cofactors, transient intermediates, and labile regulatory modifications, but ABPP probes for such species are underdeveloped. Here, we describe a versatile class of probes for this less charted hemisphere of the proteome. The use of an electron-rich hydrazine as the common chemical modifier enables covalent targeting of multiple, pharmacologically important classes of enzymes bearing diverse organic and inorganic cofactors. Probe attachment occurs by both polar and radicaloid mechanisms, can be blocked by molecules that occupy the active sites, and depends on the proper poise of the active site for turnover. These traits will enable the probes to be used to identify specific inhibitors of individual members of these multiple enzyme classes, making them uniquely versatile among known ABPP probes.

show abstract

“…Regarding the ability of β-carbolines to inhibit the MAO-A enzyme, although some authors indicate that MAO inhibitors should not be used in the treatment of pain (Mika, Zychowska, Makuch, Rojewska, & Przewlocka, 2013), MAO inhibitors like phenelzine have been shown to be effective for treating pain associated with depression (Davidson, 1985). Moreover, specific MAO-A inhibitors could have greater analgesic effects (Menkes, Fawcett, Busch, & Jones, 1995), since these specific inhibitors increase norepinephrine, DA, and 5-HT levels in the tissues (da Prada et al, 1990).…”

Section: Discussionmentioning

confidence: 99%

Long-lasting analgesic effect of the psychedelic drug changa: A case report

Oña

Troncoso

2019

Journal of Psychedelic Studies

View full text Add to dashboard Cite

Background and aims: Pain is the most prevalent symptom of a health condition, and it is inappropriately treated in many cases. Here, we present a case report in which we observe a long-lasting analgesic effect produced by changa, a psychedelic drug that contains the psychoactive N,N-dimethyltryptamine and ground seeds of Peganum harmala, which are rich in β-carbolines. Methods: We describe the case and offer a brief review of supportive findings. Results: A long-lasting analgesic effect after the use of changa was reported. Possible analgesic mechanisms are discussed. We suggest that both pharmacological and non-pharmacological factors could be involved. Conclusion: These findings offer preliminary evidence of the analgesic effect of changa, but due to its complex pharmacological actions, involving many neurotransmitter systems, further research is needed in order to establish the specific mechanisms at work.

show abstract

Monoamine Oxidase Inhibitors in Patients With Chronic Pain

Cited by 16 publications

References 4 publications

General Health, Health Care Utilization, and Medical Comorbidity in Dysthymia

General Health, Health Care Utilization, and Medical Comorbidity in Dysthymia

Activity-Based Hydrazine Probes for Protein Profiling of Electrophilic Functionality in Therapeutic Targets

Long-lasting analgesic effect of the psychedelic drug changa: A case report

Contact Info

Product

Resources

About